About Neuroblastoma

What is Neuroblastoma?

Neuroblastoma is a rare and aggressive childhood cancer that affects around 100 children each year in the UK. It has one of the lowest survival rates. Read more

Neuroblastoma Symptoms

Know the signs and symptoms of neuroblastoma. Read more

Diagnosis

Learn more about what to expect if you suspect your child has neuroblastoma. Read more

Risk Groups and Staging

Neuroblastoma is diagnosed with an associated stage and risk group. Learn more about each one and what it means. Read more

Treatment For Neuroblastoma

Treatment for neuroblastoma varies greatly depending on a child's circumstances. Here you can read about common therapies used for high-risk neuroblastoma in the UK. Read more

Some families explore the option of clinical trials in addition to standard therapies, often when frontline treatment isn't working as it should, or as maintenance therapy to avoid a relapse. Learn more about how clinical trials work. Read more

Latest

Raffle for Jude

Jude is 4. He lives in Sheffield with his family. He is battling cancer & needs pioneering treatment in America. We can help get him there…
Rock N Roll for Kayla

Kayla from Norwich is facing a huge challenge, so rock n rollers unite.
Complaints and Compliments

We are committed to conducting our work with honesty and integrity. We have high standards and always have the best of intentions, which means we don’t like to get things wrong. We welcome all compliments and complaints to tell us how we’re doing and so when it’s needed, we can put things right and improve.
Kathryn's Birthday fundraiser for Jude

I am fundraising to support Jude and his family's campaign to get medical treatment in America.

Beau's Campaign

Beau was diagnosed with high-risk neuroblastoma, an aggressive childhood cancer that has a 40-50% chance of long-term survival at diagnosis, in December 2020. Her family are appealing for your help to raise £317,000 by May 2022.
Flora's Campaign

In January 2021 Flora was diagnosed with Autism Spectrum Disorder, and just three months later her parents were given the devastating news she had high-risk neuroblastoma. Her family are appealing for your help to raise £252,000 by August 2022 for Flora to enrol on the Bivalent Vaccine clinical trial in New York that aims to stop her neuroblastoma from coming back.
Jude's Campaign

Jude is a Dinosaur and animal-loving three-year-old. In July 2021 Jude was diagnosed with high-risk neuroblastoma, a rare and aggressive childhood cancer that has a 40-50% chance of long-term survival at diagnosis.
Joseph Yeandle

We are devastated to share the news that beautiful Joseph has sadly passed away.
Maysaa's Campaign

Four-year-old Maysaa was diagnosed with high-risk neuroblastoma, an aggressive childhood cancer that has a 40-50% chance of long-term survival at diagnosis, in March 2021. Her family are asking for your support to raise £106,000 by August 2022 for Maysaa to enrol on the DFMO study in Charlotte that aims to stop her neuroblastoma from coming back.
Chloe’s Journey

Beautiful Chloe passed away on the 4th of February 2022.
Eden's Campaign

Six-year-old Eden was diagnosed with high-risk neuroblastoma, an aggressive childhood cancer that has a 40-50% chance of long-term survival at diagnosis, in April 2021.
Kayla's Campaign

Three-year-old Kayla was diagnosed with high-risk neuroblastoma in May 2021. Kayla’s parents are asking for your help to raise £221,000 by November 2022 for Kayla to enrol on the bivalent vaccine clinical trial in New York that aims to stop her neuroblastoma from coming back.
Peter's Campaign

11-year-old Peter was diagnosed with neuroblastoma in early 2019. Devastatingly he relapsed in August 2020 after being clear of disease for 6 months. Thanks to your incredible fundraising and support, Peter was able to enrol on the DFMO study in Charlotte at the end of January 2022.
Dulcie's Campaign

In December 2021, five-year-old Dulcie was diagnosed with high-risk neuroblastoma, a rare and aggressive childhood cancer that has a 40-50% chance of long-term survival at diagnosis.